BACKGROUND: Axitinib is an oral, potent, small molecule tyrosine kinase inhibitor with selective inhibition of VEGFR 1,2, 3, as well as inhibition of potential downstream effectors of the EGFR pathway. Given the upregulation of EGFR and VEGFR in head and neck squamous cell carcinoma, treatment with axitinib holds promise as a rational targeted therapy. PATIENTS AND METHODS: Patients with unresectable, recurrent or metastatic head and neck squamous cell carcinoma were included in this open label, single arm, phase II trial. Primary endpoint was 6 month progression free survival. All patients received single agent axitinib with planned dose escalation based on tolerability. A planned interim efficacy analysis was performed after enrollment of 30 patients. RESULTS: Forty-two patients were registered, 30 were evaluable. While treatment was well-tolerated with no severe bleeding events, only 19 patients were able to achieve full planned dose. The best overall response rate was 6.7% (two partial responses) with a disease control rate of 76.7%. Median progression free survival was 3.7 months (95% Confidence Interval (CI): 3.5-5.7) and overall survival was 10.9 months (95% CI: 6.4-17.8). Exploratory analysis demonstrated that patients with a smaller sum of diameter of target lesions experienced improved response rates, and better progression-free and overall survival. CONCLUSION: Treatment with single agent axitinib should be considered due to acceptable toxicity profile and favorable median overall survival compared to standard therapies.
BACKGROUND:Axitinib is an oral, potent, small molecule tyrosine kinase inhibitor with selective inhibition of VEGFR 1,2, 3, as well as inhibition of potential downstream effectors of the EGFR pathway. Given the upregulation of EGFR and VEGFR in head and neck squamous cell carcinoma, treatment with axitinib holds promise as a rational targeted therapy. PATIENTS AND METHODS: Patients with unresectable, recurrent or metastatic head and neck squamous cell carcinoma were included in this open label, single arm, phase II trial. Primary endpoint was 6 month progression free survival. All patients received single agent axitinib with planned dose escalation based on tolerability. A planned interim efficacy analysis was performed after enrollment of 30 patients. RESULTS: Forty-two patients were registered, 30 were evaluable. While treatment was well-tolerated with no severe bleeding events, only 19 patients were able to achieve full planned dose. The best overall response rate was 6.7% (two partial responses) with a disease control rate of 76.7%. Median progression free survival was 3.7 months (95% Confidence Interval (CI): 3.5-5.7) and overall survival was 10.9 months (95% CI: 6.4-17.8). Exploratory analysis demonstrated that patients with a smaller sum of diameter of target lesions experienced improved response rates, and better progression-free and overall survival. CONCLUSION: Treatment with single agent axitinib should be considered due to acceptable toxicity profile and favorable median overall survival compared to standard therapies.
Entities:
Keywords:
Axitinib; Head and neck cancer; Squamous cell carcinoma; Tyrosine kinase inhibitor; Vascular endothelial growth factor receptor
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: E E W Cohen; M Tortorici; S Kim; A Ingrosso; Y K Pithavala; P Bycott Journal: Cancer Chemother Pharmacol Date: 2014-10-15 Impact factor: 3.333
Authors: Anil K Chaturvedi; Eric A Engels; Ruth M Pfeiffer; Brenda Y Hernandez; Weihong Xiao; Esther Kim; Bo Jiang; Marc T Goodman; Maria Sibug-Saber; Wendy Cozen; Lihua Liu; Charles F Lynch; Nicolas Wentzensen; Richard C Jordan; Sean Altekruse; William F Anderson; Philip S Rosenberg; Maura L Gillison Journal: J Clin Oncol Date: 2011-10-03 Impact factor: 44.544
Authors: Rekha Gyanchandani; Daisuke Sano; Marcus V Ortega Alves; Jonah D Klein; Beth A Knapick; Sanders Oh; Jeffrey N Myers; Seungwon Kim Journal: Oral Oncol Date: 2013-04-24 Impact factor: 5.337
Authors: J Simon W Stewart; Ezra E W Cohen; Lisa Licitra; Carla M L Van Herpen; Chonlakiet Khorprasert; Denis Soulieres; Pavel Vodvarka; Danny Rischin; Avgust M Garin; Fred R Hirsch; Marileila Varella-Garcia; Serban Ghiorghiu; Laura Hargreaves; Alison Armour; Georgina Speake; Alan Swaisland; Everett E Vokes Journal: J Clin Oncol Date: 2009-03-16 Impact factor: 44.544
Authors: Carole Fakhry; William H Westra; Sigui Li; Anthony Cmelak; John A Ridge; Harlan Pinto; Arlene Forastiere; Maura L Gillison Journal: J Natl Cancer Inst Date: 2008-02-12 Impact factor: 13.506
Authors: Robert J Motzer; Bernard Escudier; Piotr Tomczak; Thomas E Hutson; M Dror Michaelson; Sylvie Negrier; Stephane Oudard; Martin E Gore; Jamal Tarazi; Subramanian Hariharan; Connie Chen; Brad Rosbrook; Sinil Kim; Brian I Rini Journal: Lancet Oncol Date: 2013-04-16 Impact factor: 41.316
Authors: Denis Soulieres; Neil N Senzer; Everett E Vokes; Manuel Hidalgo; Sanjiv S Agarwala; Lillian L Siu Journal: J Clin Oncol Date: 2004-01-01 Impact factor: 44.544
Authors: Paul L Swiecicki; Emily Bellile; Assuntina G Sacco; Alexander T Pearson; Jeremy M G Taylor; Trachette L Jackson; Douglas B Chepeha; Matthew E Spector; Andrew Shuman; Kelly Malloy; Jeffrey Moyer; Erin McKean; Scott McLean; Ammar Sukari; Gregory T Wolf; Avraham Eisbruch; Mark Prince; Carol Bradford; Thomas E Carey; Shaomeng Wang; Jacques E Nör; Francis P Worden Journal: Invest New Drugs Date: 2016-05-26 Impact factor: 3.850
Authors: Shruti Choudhary; Arpit Doshi; Lerin Luckett-Chastain; Michael Ihnat; Ernest Hamel; Susan L Mooberry; Aleem Gangjee Journal: Bioorg Med Chem Date: 2021-02-12 Impact factor: 3.641
Authors: Nabil F Saba; Pooja Vijayvargiya; Jan B Vermorken; Juan P Rodrigo; Stefan M Willems; Nina Zidar; Remco de Bree; Antti Mäkitie; Greg T Wolf; Athanassios Argiris; Yong Teng; Alfio Ferlito Journal: Cancers (Basel) Date: 2022-02-25 Impact factor: 6.639
Authors: Aini Hyytiäinen; Wafa Wahbi; Otto Väyrynen; Kauko Saarilahti; Peeter Karihtala; Tuula Salo; Ahmed Al-Samadi Journal: Front Oncol Date: 2021-06-14 Impact factor: 6.244